Research & Development
Investigational Therapeutic for Episodic Cardiovascular Conditions
We are studying our lead investigational candidate, etripamil, for the acute treatment of patients with paroxysmal supraventricular tachycardia (PSVT) and atrial fibrillation (AFib), as well as other episodic cardiovascular conditions—wherever you are when they occur.
To ensure the safety of trial participants, new processes have been put in place to reduce the risks associated with the COVID-19 pandemic. These potential changes include, but are not limited to, the use of tele-medicine to conduct study visit procedures, conduct of study procedures outside of the clinical site (i.e., at a patient’s home) by site personnel or by trained but non-site personnel, and the distribution of investigational products by alternative secure delivery methods
Clinical trials are a critical part of the drug development process designed to assess an investigational agent’s safety and effectiveness in treating a disease, adding to the scientific body of knowledge on diseases and how they may be treated.
For information regarding access to Milestone’s clinical trials, please visit clinicaltrials.gov.
Phase 3 Clinical Program
Milestone’s pivotal Phase 3 program of etripamil in PSVT, which was designed in consultation with U.S. and European Union regulatory authorities, consists of three distinct trials evaluating the safety and efficacy of etripamil in at-home settings and without the need for medical supervision.
Open-label safety extension trial
See a description of our Node-302 Phase 3 clinical trial clinical.trials.gov
Pivotal efficacy trial of a repeat administration of etripamil
See a description of our Rapid Node-301 Part 2 Phase 3 clinical trial clinical.trials.gov
Ongoing global safety trial and the largest trial ever conducted in PSVT
See a description of our Node-303 Phase 3 clinical trial clinical.trials.gov
Phase 2 Clinical Program
We have initiated Phase 2 clinical trials in atrial fibrillation and plan to initiate trials to establish proof-of-concept for the broader use of etripamil in other episodic cardiovascular conditions.
See a description of our ReVeRA Phase 2 proof-of-concept trial on clinicaltrials.gov